Ratings by H.C. Wainwright (Edwin Zhang)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 12/22/2021 | Aldeyra Therapeutics | ALDX | Maintain | Buy (N/A) |
|
Details | ||
| 12/21/2021 | Reneo Pharmaceuticals | RPHM | New Coverage | Buy (N/A) |
6.88 (1.74) |
-74.71% | Details | |
| 12/20/2021 | Calliditas Therapeutics | CALT | Maintain | Buy (N/A) |
|
Details | ||
| 9/30/2021 | Ultragenyx Pharma | RARE | New Coverage | Buy (N/A) |
86.12 (42.37) |
-50.8% | Details | |
| 6/24/2021 | Liminal BioSciences, Inc. | LMNL | Downgrade | Neutral (Buy) |
4.07 (8.50) |
108.85% | Details | |
| 6/7/2021 | LogicBio Therapeutics | LOGC | New Coverage | Buy (N/A) |
4.68 (2.07) |
-55.77% | Details | |
| 4/7/2021 | FibroGen | FGEN | Downgrade | Neutral (Buy) |
34.64 (1.15) |
-96.68% | Details | |
| 2/18/2021 | Liminal BioSciences, Inc. | LMNL | New Coverage | Buy (N/A) |
5.74 (4.07) |
-29.09% | Details |
